Amryt Pharma plc (NASDAQ:AMYT) saw strong trading volume on Thursday . 9,355 shares were traded during trading, a decline of 56% from the previous session’s volume of 21,451 shares.The stock last traded at $14.27 and had previously closed at $14.23.
A number of equities analysts have recently issued reports on the company. Maxim Group assumed coverage on Amryt Pharma in a research note on Wednesday, March 31st. They set a “buy” rating and a $27.00 target price for the company. Zacks Investment Research downgraded Amryt Pharma from a “hold” rating to a “sell” rating in a research note on Tuesday, March 9th. Finally, SVB Leerink reissued a “buy” rating and set a $40.00 target price on shares of Amryt Pharma in a research note on Sunday, March 7th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $33.40.
The firm has a market cap of $511.96 million and a price-to-earnings ratio of -16.60. The business has a fifty day moving average of $14.12 and a two-hundred day moving average of $13.40.
About Amryt Pharma (NASDAQ:AMYT)
Amryt Pharma plc, a biopharmaceutical company, develops and commercializes therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy.
Further Reading: What is the Russell 2000 Index?
Receive News & Ratings for Amryt Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amryt Pharma and related companies with MarketBeat.com's FREE daily email newsletter.